Eyelash Serum - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The eyelash serum market size is projected to reach USD 1.03 billion in 2025 and USD 1.10 billion in 2026, before increasing to USD 1.57 billion by 2031, registering a CAGR of 7.37% from 2026 to 2031. This report is Segmented by Product Type (Growth, Strengthening Serums, and More), Category (Conventional and Organic), Price Range (Mass and Premium), Distribution Channel (Hypermarkets/Supermarkets, Specialty Beauty Stores, Online Retail, and Others), and Geography (North America, Europe, Asia-Pacific, South America, and Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global Eyelash Serum Market Trends and Insights

Non-invasive alternatives to eyelash extensions and false lashes

The shift from professional lash treatments to at-home serums serves as the category’s primary demand driver. This shift does not reflect trend-driven volatility; rather, it indicates a fundamental reallocation of beauty spending toward daily-use cosmeceuticals that deliver visible and measurable results without professional intervention. Salon eyelash extensions use adhesive bonding agents that can cause cumulative follicle stress. Repeat users often develop traction alopecia or contact dermatitis, creating a clinically driven entry point for growth serums. Economics further support this behavior: a three-month supply of a premium serum priced at USD 48 replaces recurring monthly extension costs that typically exceed USD 100-200 per appointment. The post-extension repair cycle further expands the category. Consumers who discontinue extensions often need conditioning and strengthening serums to rehabilitate damaged follicles before restarting a growth serum regimen, which structurally broadens the product portfolio beyond single-SKU purchases. This dynamic is most pronounced in North America and South Korea, where extension penetration rates are highest and the clean-beauty movement provides additional cultural momentum.

Social commerce and influencer-led product discovery

Social commerce has shortened the awareness-to-purchase cycle for lash enhancement products more than most beauty subcategories, giving brands with strong creator relationships a structural distribution advantage over those that depend on traditional retail sell-in timelines. In 2024, TikTok became the second-most-popular social commerce platform in the United States, with 26% of online shoppers purchasing products through the app. UKLASH, a direct-to-consumer lash serum brand, reported 55% revenue growth from 2020 to 2024, with more than 40% of its sales now generated through TikTok Shop UK live streams. Such a concentration of social-channel revenue would have been difficult to imagine for a beauty brand five years ago. K-beauty brand COSNORI is expected to enter Costco in the United States in September 2025 with its Long Active Eyelash Serum and sell out within one month, supported by prior Amazon momentum and creator-amplified social proof. The compliance dimension of influencer marketing is also tightening. In January 2025, the United States National Advertising Division (NAD) is expected to recommend that NuOrganic Cosmetics discontinue TikTok and Instagram posts containing unsupported lash growth claims, signaling that the social commerce layer faces increasing regulatory scrutiny.

Periocular safety and irritation concerns

Consumer-reported adverse effects in the periocular zone remain the category’s most persistent demand suppressor, while the gap between clinical risk communication and consumer awareness continues to widen. A 2025 consumer survey in Japan, conducted among 1,000 female eyelash serum users aged 20 to 50, found that 97.5% of respondents who experienced side effects, including pigmentation and irritation, did not consult a physician. This finding highlights inadequate product-level risk disclosure and material latent liability for brands. The US Modernization of Cosmetics Regulation Act (MoCRA) mandates cosmetic product registration from July 2024. By January 2025, the FDA’s database is expected to contain 589,762 unique active cosmetic listings, 16 times the pre-MoCRA total, significantly increasing the likelihood that adverse event reports related to periocular products will draw federal enforcement attention. A comprehensive review published in the Journal of Cosmetic Dermatology further noted that current US law does not require FDA pre-market efficacy or safety assessments for over-the-counter eyelash serums. This regulatory gap creates liability exposure for brands while allowing underdisclosed actives to enter the consumer market. The convergence of expanded MoCRA enforcement visibility and the EU’s prostaglandin opinion increases the likelihood of coordinated regulatory scrutiny across the two largest serum markets within the next two years.

Other drivers and restraints analyzed in the detailed report include:

• Clean-label and prostaglandin-free formulation demand
• EU prostaglandin opinion accelerating peptide substitution
• Counterfeit products and claim-compliance risk

Segment Analysis

Strengthening serums are projected to record the highest growth rate in the product type segmentation, advancing at a CAGR of 8.46% during 2026-2031 and outpacing the overall market. Growth serums are expected to account for a 49.51% share in 2025, anchoring the category’s revenue base. The difference in growth rates across sub-segments reflects a post-extension behavioral cycle: consumers who discontinue professional lash treatments often need conditioning and strengthening formulations to restore follicle integrity before resuming a growth serum regimen. This shift expands demand beyond the single-function growth serum archetype. Conditioning serums address the hydration and flexibility needs of lashes stressed by adhesive removal, while volumizing serums appeal to consumers seeking cosmetic density gains without a clinically validated growth mechanism. Brands are also driving a clinically oriented convergence of functionality across sub-segments by developing dual- and triple-action serums that combine growth actives with conditioning and strengthening peptides. This approach blurs category distinctions and supports premium price positioning.

Peer-reviewed evidence supports this multi-modal formulation architecture. A clinical trial published in the Journal of Cosmetic Dermatology documented measurable lash density improvements using a prostaglandin-free peptide and glycosaminoglycan hybrid formulation, suggesting that multi-modal actives can meet the evidentiary standard previously associated with single-function prostaglandin formulas. The convergence also supports shelf productivity, as specialty beauty retailers and online DTC platforms increasingly favor multi-benefit SKUs that generate higher units per transaction and repeat purchase rates than single-function formulas. OLAPLEX’s LashBond Building Serum, launched in March 2024 with the company’s patented bond-building peptide complex and positioned as lengthening, thickening, and hydrating, demonstrates how crossover ingredient science from adjacent categories can redefine the product type segmentation.

The organic formulation tier is expected to account for approximately 11.38% of the market in 2025 and register a CAGR of 9.11% during 2026-2031. This growth rate exceeds the overall market CAGR and the rate projected for the fastest-growing geography. A convergence of regulatory pressure and consumer demand is accelerating the category’s transition toward clean beauty faster than many brand roadmaps anticipated. Conventional formulations are expected to retain 88.62% of the market in 2025, reflecting the category’s long-standing reliance on synthetically derived actives with efficacy claims established over more than a decade. Niche wellness consumers are not the only drivers of the organic tier’s growth. The SCCS opinion issued in February 2026 is expected to push mainstream brands toward botanical and peptide actives, which naturally align with organic certification criteria such as Ecocert’s Cosmos Organic standard. UKLASH founder Nima Pourian’s August 2025 launch of “groa,” a brand positioned as 99% naturally sourced, prostaglandin-free, and dermatologically tested for Gen Z and Gen Alpha consumers, indicates that the organic tier is expanding toward accessible price points, rather than only toward prestige positioning.

The shift from conventional to organic formulations is not cost-neutral. Certified organic actives involve higher sourcing costs, shorter shelf lives, and greater formulation complexity, requiring advanced emulsion technology. This dynamic creates a competitive bifurcation, with organic growth concentrated among mid-to-premium brands that have the research and development infrastructure to manage the transition, rather than being evenly distributed across market tiers. The mass organic segment remains underdeveloped compared with prestige, creating a potential white space for brands that can develop cost-effective botanical active systems at accessible price points. This opportunity is particularly relevant in Asia-Pacific markets, where local botanical ingredient sourcing offers a cost advantage that Western formulators may not have.

Complete Report Scope:

• Product Type
  • Growth Serums
  • Conditioning Serums
  • Volumizing Serums
  • Strengthening Serums
  • Other Product Types
• Category
  • Conventional
  • Organic
• Price Range
  • Mass
  • Premium
• Distribution Channel
  • Hypermarkets and Supermarkets
  • Specialty Beauty Stores
  • Online Retail Stores
  • Other Distribution Channels
• Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Belgium
    • Poland
    • Netherlands
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Thailand
    • Singapore
    • Indonesia
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Peru
    • Chile
    • Rest of South America
  • Middle East and Africa
    • United Arab Emirates
    • South Africa
    • Saudi Arabia
    • Nigeria
    • Egypt
    • Morocco
    • Turkey
    • Rest of Middle East and Africa

Geography Analysis

North America is expected to hold 38.9% of the eyelash serum market in 2025. High beauty spending, established direct-to-consumer channels, and broad specialty retail availability support the region’s position and strengthen consumer access to premium and niche lash-enhancing products. The United States remains the largest contributor to regional demand, supported by strong brand awareness, frequent product launches, and high adoption of at-home beauty solutions. GrandeLASH-MD accounted for 62% of US prestige lash-serum sales in 2024, according to company-cited Circana data in the supplied research. Canada’s restrictions on prostaglandins and their analogs in cosmetics are accelerating the shift toward alternative formulations, particularly peptide-, vitamin-, and botanical-based products positioned as safer long-term options.

Europe remains a major regional cluster, driven by demand in the United Kingdom, Germany, France, Italy, and Spain. Consumers in these markets continue to support growth through interest in premium beauty, clean-label positioning, and salon-recommended products. The SCCS opinion expected in February 2026 could create a clear formulation challenge for products using MDN, IPCP, or DDDE. If restrictions advance, brands may need to reformulate or adjust their European product ranges to meet evolving safety and compliance requirements. This shift may temporarily increase costs due to product testing, ingredient replacement, and packaging updates, but it could also benefit companies that already offer transparent peptide- or botanical-based systems. RevitaLash is expanding its United Kingdom operations, indicating continued interest in local salon and specialty retail relationships.

Asia-Pacific is forecast to grow at a CAGR of 8.98% through 2031, the highest regional rate in the supplied forecast. China, South Korea, Japan, India, and Southeast Asia are key markets, supported by rising online beauty activity, expanding social commerce, and active regional product innovation. Anfar reported that its ScalpD eyelash serum series reached the top domestic position in Japan by value and volume in 2025, reflecting strong consumer interest in specialized lash-care products. South Korea is both a demand center and a source of K-beauty product development, with brands using trend-driven formats and ingredient innovation to expand category visibility. South America remains smaller by revenue, with Brazil and Colombia contributing demand through growing beauty spending and improving access to international brands. Saudi Arabia and the United Arab Emirates offer longer-term potential, supported by beauty spending, premium retail development, and broader product availability across modern trade and online channels.

List of Companies Covered in this Report:

• L'Oréal S.A.
• The Estée Lauder Companies Inc.
• Shiseido Company, Limited
• Grande Cosmetics LLC
• Athena Cosmetics, Inc.
• RevitaLash Cosmetics
• Skin Research Laboratories
• RapidLash
• Pacifica Beauty LLC
• E.l.f. Cosmetics, Inc.
• JB Cosmetics Group
• Talika Group
• Obagi Medical
• Topix Pharmaceuticals, Inc.
• Neora
• OLAPLEX, Inc.
• UKLASH
• LashFood
• Ardell International Inc.
• Rodan + Fields

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support